Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.
In all, 168 patients who had progressed on anti-angiogenic drugs were randomized to receive 0.3, 2, or 10 mg/kg nivolumab every 3 weeks. Patients on the trial were heavily pretreated – receiving nivolumab as second-, third-, or fourth-line therapy.
The response rate seen in all three arms was approximately 20%, while median PFS ranged from 2.7 to 4.0 months. The most striking results from this trial, Motzer says, is that many responses were durable.
The median OS was longer than expected, Motzer says, as it ranged from 18.7 to 25.0 months. Nivolumab was well tolerated, too, as just 11% of patients experienced a grade 3/4 adverse event.
<<< View more from the 2014 ESMO Congress